Sugi Predict

Sugi Predict / Targets / TFPI2

TFPI2

Tissue factor pathway inhibitor 2 · P48307 · TFPI2 on Sugi Atlas →

2,735 patent compounds predicted against TFPI2, 1,255 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2332631 SCHEMBL2332631 0.77 11/20
SCHEMBL9880167 SCHEMBL9880167 0.75 11/20
SCHEMBL13311565 SCHEMBL13311565 0.75 11/20
SCHEMBL2334396 SCHEMBL2334396 0.73 11/20
SCHEMBL9880150 SCHEMBL9880150 0.73 11/20
SCHEMBL12390201 SCHEMBL12390201 0.68 11/20
SCHEMBL9880174 SCHEMBL9880174 0.90 10/20
SCHEMBL13311562 SCHEMBL13311562 0.90 10/20
SCHEMBL12390245 SCHEMBL12390245 0.73 10/20
Lb-100 Lb-100 (SCHEMBL2832350) 1.00 9/20
Lb-100 Lb-100 (SCHEMBL9880148) 1.00 9/20
Lb-100 Lb-100 (SCHEMBL12390164) 1.00 9/20
Endothall Endothall (SCHEMBL2332204) 0.64 9/20
SCHEMBL2330162 SCHEMBL2330162 0.55 9/20
SCHEMBL1572846 SCHEMBL1572846 0.74 8/20
SCHEMBL2326970 SCHEMBL2326970 0.68 8/20
SCHEMBL9880151 SCHEMBL9880151 0.68 8/20
SCHEMBL2330157 SCHEMBL2330157 0.53 8/20
Endothall Endothall (SCHEMBL55158) 1.00 7/20
Endothall Endothall (SCHEMBL3494764) 1.00 7/20

Clinical trials — most relevant to TFPI2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage PHASE4NOT_YET_RECRUITING
Vorapaxar on Thrombin Generation and Coagulability PHASE4COMPLETED
Study of TAK-672 in Participants With Acquired Hemophilia A PHASE2/PHASE3COMPLETED
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes PHASE2COMPLETED
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 PHASE2COMPLETED
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose PHASE1COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects PHASE1COMPLETED
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration PHASE1COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System PHASE1COMPLETED
The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure EARLY_PHASE1COMPLETED
Tissue Factor Expression in Stage C Heart Failure nanCOMPLETED
Heparin Management During Cardiopulmonary Bypass in Children nanCOMPLETED
Factor XI Levels in Acute Ischemic Stroke nanCOMPLETED
TFPI Levels in Haemophilia A and B Patients nanUNKNOWN
Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients nanUNKNOWN
Heparin or Enoxaparin in Patients With Cancer nanCOMPLETED
Correlation Between PT and INR to Factor 7 nanUNKNOWN
Genetic Epidemiology of Venous Thromboembolism nanCOMPLETED
Monitoring of Anti-TFPI in Hemophilia nanRECRUITING
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion nanRECRUITING
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage. nanRECRUITING
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia nanCOMPLETED
TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects. nanCOMPLETED
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster. nanRECRUITING
Thrombin Regulated Platelet Activation nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study nanCOMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TFPI2 binder may also engage these)

ProteinNameSimilarity
Q7YRQ8 — 1.000 Q7YRQ8 →
P00992 — 0.998 P00992 →
O35536 — 0.997 O35536 →
P0DN15 — 0.997 P0DN15 →
P04815 — 0.995 P04815 →
Q8MVC4 — 0.995 Q8MVC4 →
B5KL33 — 0.994 B5KL33 →
A8Y7N8 — 0.994 A8Y7N8 →
Q28864 — 0.994 Q28864 →
E5AJX3 — 0.994 E5AJX3 →
I2G9B4 — 0.994 I2G9B4 →
P0DN16 — 0.993 P0DN16 →
P0DN06 — 0.993 P0DN06 →
W4VSH9 — 0.993 W4VSH9 →
SPINT2 Kunitz-type protease inhibitor 2 0.993 landscape →
P00974 — 0.992 P00974 →
Q9R097 — 0.992 Q9R097 →
A8Y7N7 — 0.992 A8Y7N7 →
F8J2F6 — 0.992 F8J2F6 →
Q90W97 — 0.992 Q90W97 →
P0DN10 — 0.992 P0DN10 →
A8Y7N6 — 0.992 A8Y7N6 →
P00991 — 0.992 P00991 →
Q9W728 — 0.992 Q9W728 →
D2Y2Q2 — 0.992 D2Y2Q2 →
P0DJ80 — 0.992 P0DJ80 →
B2ZBB6 — 0.991 B2ZBB6 →
B5G6G6 — 0.991 B5G6G6 →
Q2ES48 — 0.991 Q2ES48 →
P82966 — 0.991 P82966 →